home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480654.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
2KB
|
40 lines
Document 0654
DOCN M9480654
TI [The stakes in preventing opportunistic MAI infections in AIDS. From an
interview with Dr. Patrick Philibert]
DT 9410
AU Philibert P
SO Allerg Immunol (Paris). 1994 Apr;26(4):145-8. Unique Identifier :
AIDSLINE MED/94304497
AB Development of HIV infection is littered with many pathological episodes
of which the physical and psychological repercussions on the patient are
full of consequences. In this context, full co-operation between the
hospital services and general practitioners is fundamental, from the
moment of the announcement of seropositivity, to place under
anti-retroviral treatment and to follow the pathological events.
Opportunistic infections that threaten the life of the patient are
severe because of the fall in the level of CD4 lymphocytes. Nowadays it
is important to start prophylactic treatments and to make the patient
understand the fight to follow these treatments that alone can help to
maintain his autonomy and quality of life. The quality of the
relationship established between the practitioner and patient is here
very important. At the start of prophylactic treatment for several
opportunistic infections in AIDS, such as pneumocystosis or
toxoplasmosis, it is essential to have available an effective
therapeutic strategy for infection by Mycobacterium avium complex (MAC).
In effect, these serious infections following after the development of
AIDS, graviously threaten the life of patients and their probability to
survive. Today, practitioners have available rifabutine (Ansatipine)
which is an efficacious treatment for MAC infections. It is sure that
many patients will find benefit.
DE Antiviral Agents/THERAPEUTIC USE AIDS-Related Opportunistic
Infections/EPIDEMIOLOGY/MICROBIOLOGY/ *PREVENTION &
CONTROL/PARASITOLOGY English Abstract Human HIV Infections/DRUG
THERAPY Leukocyte Count Mycobacterium avium-intracellulare
Infection/EPIDEMIOLOGY/ *PREVENTION & CONTROL Rifabutin/THERAPEUTIC
USE T4 Lymphocytes INTERVIEW JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).